Holen Sie sich die Stockscreener-App
16.90
0.48%
-0.07
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
DFTX: RBC Capital Raises Price Target for Definium Therapeutics - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Definium launches educational campaign on LSD for mental health - Investing.com
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com Nigeria
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care - Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Update - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns - Yahoo Finance
Deinium Therapeutics (DFTX) Is Up 8.7% After Rebrand And DT120 Anxiety Pipeline UpdateWhat's Changed - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 1-Year 110% Surge? - Yahoo Finance
DFTX (Definium Therapeutics) Momentum Rank : 10 (As of Jan. 18, 2026) - GuruFocus
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress - Sahm
Definium Therapeutics stock hits 52-week high at 15.3 USD By Investing.com - Investing.com Nigeria
Definium Therapeutics stock hits 52-week high at 15.3 USD - Investing.com
Five new option listings and one option delisting on January 15th - TipRanks
MNMD: DT120 targets rapid, lasting relief for anxiety and depression, with pivotal data due in 2024 - TradingView — Track All Markets
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 - Business Wire
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol "DFTX" Effective January 15, 2026 - Yahoo Finance
Mind Medicine Inc. will Change its Ticker to DFTX from MNMD - marketscreener.com
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - Sahm
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 5.6%Here's What Happened - MarketBeat
Definium Therapeutics Rebrands and Highlights 2026 Pipeline - TipRanks
Definium Therapeutics (MNMD) Announces Rebranding and Ticker Cha - GuruFocus
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $339,151.65 in Stock - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpTime to Buy? - MarketBeat
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
MindMed Announces New Employee Inducement Grant - Business Wire
MindMed Reports Q3 2025 Financial Results and Business Updates - Business Wire
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Business Wire
MindMed to Report Q3 2025 Financial Results on November 6, 2025 - Business Wire
Mind Medicine says it announces pricing of $225 million public offering at $12.25 per share - marketscreener.com
Mind Medicine Nears Pivotal Year: Strong Fundamentals Make It A Buy (NASDAQ:MNMD) - Seeking Alpha
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - The Motley Fool
Mind Medicine stock upgraded at Oppenheimer (MNMD:NASDAQ) - Seeking Alpha
Mind Medicine Inc.(NasdaqGS: MNMD) added to Russell 3000 Value Index - marketscreener.com
MindMed to Participate in June Investor Conferences - marketscreener.com
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer - marketscreener.com
MindMed Announces New Employee Inducement Grants - marketscreener.com
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference - marketscreener.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - marketscreener.com
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - marketscreener.com
MindMed Appoints Matt Wiley as Chief Commercial Officer - marketscreener.com
MindMed to Present at Leerink's Global Healthcare Conference 2025 - marketscreener.com
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - marketscreener.com
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call (MNMD) - Seeking Alpha
MindMed to Be Added to the Nasdaq Biotechnology Index - marketscreener.com
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate (NASDAQ:MNMD) - Seeking Alpha
Psychedelic Stocks: Focus On Their Cash - Seeking Alpha
Medical journal retracts three articles related to MDMA for PTSD - Seeking Alpha
MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy (MNMD) - Seeking Alpha
UN Warns of Health Dangers in Commercial Psychedelic Drug Use - Bloomberg.com
De-Risking Psychedelics: Compass Pathways, Cybin And Atai - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Mind Medicine Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD - marketscreener.com
FCM MM Holdings LLC Sends a Letter to Mind Medicine Inc - marketscreener.com
MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics (NASDAQ:MNMD) - Seeking Alpha
Why Mind Medicine (MindMed) Stock Is Crashing Today - The Motley Fool
Wall Street Says This Stock Can Deliver a 543% Return. Should You Listen? - The Motley Fool
Why Mind Medicine Stock Crushed the Market on Friday - The Motley Fool
Mind Medicine: It’s Best To Stay Far Away From This Risky Psychedelic Stock - Seeking Alpha
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder - marketscreener.com
MindMed Enrolls First Participant in a Study of its Session Monitoring System - marketscreener.com
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC - marketscreener.com
Could Mind Medicine Be a Millionaire-Maker Stock? - The Motley Fool
Why Shares of MindMed Dropped 13% in May - The Motley Fool
Mind Medicine Stock Is Soaring After Its NASDAQ Debut. What's Next? - The Motley Fool
Mind Medicine MindMed : MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD - marketscreener.com
MindMed Appoints Robert Barrow as Chief Development Officer - marketscreener.com
3.30%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):